All In Biotech

Free tool

FAERS Monitor: Catapres-Tts-3

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018891 or its brand name (Catapres-Tts-3, Clonidine). Reports on generic versions are filed under their own applications.

Reports

2,134

Serious

564

26% of reports

Hospitalization

294

Death reported

61

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • application site pruritus347
  • application site erythema304
  • drug ineffective280
  • blood pressure increased254
  • application site rash198
  • product adhesion issue187
  • hypertension145
  • application site irritation123
  • wrong technique in product usage process100
  • headache96
  • application site vesicles83
  • blood pressure inadequately controlled83
  • product quality issue83
  • application site pain81
  • dizziness80

Reports by year received

View as table
YearReports
200446
200557
200652
2007157
2008290
2009249
2010170
201195
201270
201317
201444
201554
201668
2017103
201881
2019110
202073
202183
202252
202362
202435
202566
2026100

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,025 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
application site pruritusSignal347153.1138.951,527
application site rashSignal198144.0126.027,585
blood pressure inadequately controlledSignal83137.9111.510,991
application site vesiclesSignal83127.8103.310,183
application site erythemaSignal304115.6104.134,080
application site irritationSignal12398.482.811,651
product adhesion issueSignal18751.845.29,242
application site painSignal8136.429.42,744
blood pressure increasedSignal25416.414.63,678
hypertensionSignal1456.85.8711
product quality issueSignal836.04.9345
wrong technique in product usage processSignal1004.94.0306
drug ineffectiveSignal2802.11.9170
dizziness801.61.317
headache961.51.216

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.